HC Wainwright Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX - Free Report) had its price objective lifted by HC Wainwright from $134.00 to $145.00 in a research note published on Thursday morning, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts also recently commented on the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Truist Financial reiterated a "buy" rating and issued a $155.00 price objective (up from $151.00) on shares of BioNTech in a report on Tuesday. The Goldman Sachs Group began coverage on BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective for the company. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a report on Friday, May 30th. Finally, JPMorgan Chase & Co. reduced their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, BioNTech has an average rating of "Moderate Buy" and a consensus target price of $139.79.

BioNTech Stock Down 0.9%

BioNTech stock traded down $0.99 on Thursday, hitting $110.15. 851,163 shares of the stock traded hands, compared to its average volume of 938,773. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $26.48 billion, a P/E ratio of -52.45 and a beta of 1.29. The business's fifty day simple moving average is $98.89 and its 200 day simple moving average is $108.34. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the company earned $1.90 earnings per share. The company's revenue was down 19.5% on a year-over-year basis. As a group, sell-side analysts forecast that BioNTech will post -3.88 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the 1st quarter worth approximately $36,000. Jones Financial Companies Lllp increased its position in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. increased its position in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE bought a new position in shares of BioNTech during the 4th quarter valued at approximately $90,000. Finally, Banque Transatlantique SA bought a new position in shares of BioNTech during the 1st quarter valued at approximately $80,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.